Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).

"supplementary table 2 ) were in line with the findings of the full data set"

"Potential conflicts of interest. H. C. B. has received, in the 36 months prior to the submission of this manuscript, grants, support for traveling, consultancy fees, and honorarium from Gilead, BMS, ViiV Healthcare, Roche, and Pfizer that were not related to this project. He served as the president of the Association contre le HIV et autres infections transmissibles from 2007 to June 2022. In this function, he received support for the Swiss HIV Cohort Study from ViiV Healthcare, Gilead, BMS, and MSD. A. T. received a consultant fee from Roche and unrestricted research funding from Gilead and Roche not related to this study. D. L. B. received honoraria for advisory boards from Gilead, MSD, Pfizer, AstraZeneca, and ViiV outside of the study. H. F. G., outside of this study, reports grants from the Swiss National Science Foundation, National Institutes of Health, and the SHCS; unrestricted research grants from Gilead Sciences and the Yvonne Jacob Foundation; and personal fees from consulting, advisory boards, or data safety monitoring boards for Merck, Gilead Sciences, ViiV Healthcare, Janssen, Johnson & Johnson, GSK, and Novartis. H. F. G.’s institution received money for participation in the following clinical COVID-19 studies: 540-7773/5774 (Gilead), TICO (ACTIV-3, INSIGHT/National Institutes of Health), and Morningsky (Roche). A. R. reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, and Pfizer and an investigator-initiated trial grant from Gilead Sciences; all remuneration went to his home institution and not to A. R. personally, and all remuneration was provided outside the submitted work. A. T., outside of this study, reports SARS-CoV-2 serology grants from the Swiss National Science Foundation, the SHCS, and an unrestricted research grant from Gilead Sciences. All other authors report no potential conflicts."

"Financial support. This work was supported by Moderna (COVERALL-2); the Swiss National Science Foundation (grant 31CA30_196245 for the setup of the trial platform and the first substudy [COVERALL]; grants 177499 and 201369 for Swiss HIV Cohort Study; grant 33CS30_177522 for STCS); the Pandemiefonds of the UZH foundation (a grant for the diagnostic work to A. T.); the Promedica Foundation (research grant 14851 M to I. A. A.); the Research Foundation of the University of Basel (grant to B. S.); the Janggen Pöhn Foundation and the Swiss National Science Foundation (personal grant 323530_221860 to C. M. S.). Financial support ."

"Clinical Trials Registration.  NCT04805125 (ClinicalTrials.gov)."